Life science innovation that results in successful commercialization of new drugs, therapies, vaccines and technologies that have a value based impact on patient care is not for the faint of heart.
along with organizations like Southeast Life Sciences keeps the community connected for opportunity.
among others throughout the region help promising life science innovators fail fast or reach their next milestone in a capital efficient way.
are all present within easy reach for life science innovators of all shapes and sizes here.
From the Georgia Department of Economic Development, “The state’s research universities – which generate more than $2 billion a year in public and private R&D funding – work closely together. That’s largely because of the Georgia Research Alliance (GRA), which expands research lab capacity (in talent and technology). Since its founding in 1990, GRA has become the national model for university research collaboration and public-private investment.”
Further, “Georgia ranks 2nd in the nation for the share of its universities’ research that is funded by industry (10.6%), a reflection of the close ties between academic research and industrial innovation in Georgia. Home to the U.S. Centers for Disease Control and Prevention (CDC), American Cancer Society, and other major centers of health care research.”
Boston, San Diego, the Bay Area and other locales where life science innovation currently thrives is due in large part to their hefty pools of investors. While the Southeast has work to do to catch up in capital investments in the life sciences outside of health IT (where Atlanta leads), the volume of investors and the quantity of dollars being invested in the life sciences is growing and is likely to continue to do so.
Southeast Life Sciences envisions a world-class ecosystem for life sciences in the southeast. We cultivate, convene, and connect the Southeast entrepreneurial ecosystem to foster life science innovation and investment across the region.
We bring your next, de-risked investable opportunity
We introduce you to your investors and potential partners
We bring your next clients
We pair innovators and entrepreneurs with the right investment partners at all stages on the commercialization pathway, acquisition or exit. We provide easy access to qualified experts on life science innovation from concept to commercialization including business strategy, design and development, reimbursement, regulatory, intellectual property, marketing, preclinical and beyond.
With the 2021 edition of AdvanSE in the books, I would like to extend my gratitude to all who made it possible. From the board, to the onsite staff and program committee, to our sponsors, keynote speakers, presenters, panelists and collaborators, we could not have done it without every one
At Southeast Life Sciences one of our top priorities is introducing investors to the best the Southeast has to offer in early- and later-stage life science companies. Without further ado, meet the 2021 AdvanSE PitchRounds Presenting Companies. Each will be presenting to dozens of investors among hundreds of attendees
We’re now officially less than one month away from the 2021 edition of Southeast Life Science’s flagship event, AdvanSE. The program is now complete. Please take a moment to meet our keynote speakers. Dr. Michal Preminger Head Eastern North America Johnson & Johnson Innovation Dr. Preminger will moderate
Life science and medtech investors, are you ready to meet your next opportunity? Life science and medtech innovators, are you ready to meet your next investors or solution providers? Life science and medtech solution providers, are you ready to meet your next clients? Tech transfer colleagues, are
No matter the brilliance of the research, or researcher, life science innovation relies on a rigorous regulatory and commercialization pathway before its potential to improve lives can enter patient care, at almost any scale. Universities rely on their technology transfer offices and commercial entities like Bayer to pull high
A Southeast Life Sciences Q&A with AskBio Co-Founder and CEO Sheila Mikhail “The field of gene therapy was in a nuclear winter in 2001,” said AskBio Co-Founder and CEO Sheila Mikhail. Motivated by belief in the science of gene therapy in order to give the blind a chance